Gallo RC. The discovery of the first human retrovirus: HTLV-I and
HTLV-II. Retrovirology 2005; 2:17.
2. Mueller N. The epidemiology of HTLV-I infection. Cancer Causes and Control 1991; 2:37-52.
3. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proce Natl Acad Sci 1980; 77:7415-7419.
4. Dahmoush L, Hijazi Y, Barnes E, Stetler-Stevenson M, Abati A. Adult T-cell leukemia/lymphoma. Cancer Cytopathol 2002; 96:110-116.
5. Izumo S, Umehara F, Osame M. HTLV-I-associated myelopathy. Neuropathology 2000; 20:65-68.
6. Matutes E. Adult T-cell leukaemia/lymphoma. J Clin Pathol 2007; 60:1373-1377.
7. Osarne M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A,
et al
. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986; 1:1031-1032.
8. Araujo A, Hall WW. Human T-lymphotropic virus type II and neurological disease. Ann Neurol 2004; 56:10-19.
9. Jacobson S, Lehky T, Nishimura M, Robinson S, McFarlin DE, Dhib- Jalbut S. Isolation of HTLV-II from a patient with chronic, progressive neurological disease clinically indistinguishable from HTLV-I-associated myelopathy/tropical spastic paraparesis. Ann Neurol 2004;n 33:392-396.
10. Sheremata WA, Harrington Jr WJ, Bradshaw PA, Foung SKH, Raffanti SP, Berger JR,
et al.
Association of ‘(tropical) ataxic neuropathy’with HTLV-II. Virus Res 1993; 29:71-77.
11. Hall WW, Ishak R, Zhu SW, Novoa P, Eiraku N, Takahashi H
, et al.
Human T lymphotropic virus type II (HTLV-II): epidemiology, molecular properties, and clinical features of infection J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13:S204-S14.
12. Hedayati-Moghaddam M, Fathimoghadam F, Mashhadi IE, Soghandi L, Bidkhori H. Epidemiology of HTLV-I in Neyshabour, Northeast of Iran. Iran Red Crescent Med J 2011; 13:4244.
13. Lowis GW, Sheremata WA, Minagar A. Epidemiologic Features of HTLV-II:: Serologic and Molecular Evidence. Ann Epidemiol 2002; 12:46-66.
14. Proietti FA, Carneiro-Proietti ABF, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene 2005; 24:6058-6068.
15. Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F, Bidkhori HR, Shamsian SK, Ahmadi S,
et al
. High prevalence of HTLV-I infection in Mashhad, Northeast Iran: A population-based seroepidemiology survey. J Clin Virol 2011; 52:172-176.
16. Lal R, Heneine W, Rudolph D, Present W, Hofhienz D, Hartley T
, et al.
Synthetic peptide-based immunoassays for distinguishing between human T-cell lymphotropic virus type I and type II infections in seropositive individuals. J Clin Microbiol 1991; 29:2253-2258.
17. Rudolph DL, Lal R. Discrimination of human T-lymphotropic virus type-I and type-II infections by synthetic peptides representing structural epitopes from the envelope glycoproteins. Clin Chem 1993; 39:288-292.
18. Lillehoj E, Alexander S, Dubrule C, Wiktor S, Adams R, Tai CC,
et al
. Development and evaluation of a human T-cell leukemia virus type I serologic confirmatory assay incorporating a recombinant envelope polypeptide. J Clin Microbiol 1990; 28:2653-2658.
19. Lipka J, Santiago P, Chan L, Reyes G, Samuel K, Blattner W,
et al.
Modified Western blot assay for confirmation and differentiation of human T cell lymphotropic virus types I and II. J Infect Dis 1991; 164:400-403.
20. Roberts BD, Foung S, Lipka J, Kaplan J, Hadlock K, Reyes G,
et al.
Evaluation of an immunoblot assay for serological confirmation and differentiation of human T-cell lymphotropic virus types I and II. J Clin Microbiol 1993; 31:260-264.
21. Berini CA, Eirin ME, Pando MA, Biglione MM. Human T-cell lymphotropic virus types I and II (HTLV-I and -II) infection among seroindeterminate cases in Argentina. J Med Virol 2007; 79:69-73. Epub 2006/11/30.
22. Thorstensson R, Albert J, Andersson S. Strategies for diagnosis of HTLV-I and -II. Transfusion 2002; 42:780-791.
23. Yao K, Hisada M, Maloney E, Yamano Y, Hanchard B, Wilks R,
et al.
Human T lymphotropic virus types I and II western blot seroindeterminate status and its association with exposure to prototype HTLV-I. J Infect Dis 2006; 193:427-437.
24. Garin B, Gosselin S, Gessain A. HTLV-I/II infection in a high viral endemic area of Zaire, Central Africa: Comparative evaluation of serology, PCR, and significance of indeterminate Western blot pattern. J Med Virol 2005; 44:104-109.
25. Rouet F, Meertens L, Courouble G, Herrmann-Storck C, Pabingui R, Chancerel B
, et al
. Serological, epidemiological, and molecular differences between human T-cell lymphotropic virus Type 1 (HTLV-I)-seropositive healthy carriers and persons with HTLV-I Gag indeterminate Western blot patterns from the Caribbean. J Clin Microbiol 2001; 39:1247-1253.
26. Soldan SS, Graf MD, Waziri A, Flerlage AN, Robinson SM, Kawanishi T,
et al
. HTLV-I/II seroindeterminate Western blot reactivity in a cohort of patients with neurological disease. J Infect Dis 1999; 180:685-694.
27. Costa JMP, Segurado AC. Molecular evidence of human T-cell lymphotropic virus types 1 and 2 (HTLV-I and HTLV-II) infections in HTLV seroindeterminate individuals from São Paulo, Brazil. J Clin Virol 2009; 44:185-189.
241
28. Mangano A, Remesar M, Del Pozo A, Sen L. Human T lymphotropic virus types I and II proviral sequences in Argentinian blood donors with indeterminate Western blot patterns. J Med virol 2004; 74:323-327.
29. Zanjani D, Shahabi M. Molecular analysis of human T-cell lymphotropic virus type 1 and 2 (HTLV-I/2) seroindeterminate blood donors from Northeast of Iran; evidence of proviral tax, env, and gag sequences. Retrovirology 2011; 8:1-.
30. De BK, Srinivasan A. Detection of human immunodeficiency virus (HIV) and human lymphotropic virus (HTLV) type I or II dual infections by polymerase chain reaction. Oncogene 1989; 4:1533.
31. Vrielink H, Zaaijer H, Cuypers H, Poel CL, Woerdeman M, Lelie P,
et al.
Evaluation of a New HTLV-I/II Polymerase Chain Reaction. Vox Sang 2003;72:144-147.
32. Hjelle B, Cyrus S, Swenson S, Mills R. Serologic distinction between human T-lymphotropic virus (HTLV) type I and HTLV type II. Transfusion 1991; 31:731-736.
33. Abrams A, Akahata Y, Jacobson S. The prevalence and significance of HTLV-I/II seroindeterminate Western blot patterns. Viruses 2011; 3:1320-1331. Epub 2011/10/14.
34. Vandamme AM, Van Laethem K, Liu HF, Van Brussel M, Delaporte E, de Castro Costa CM,
et al
. Use of a generic polymerase chain reaction assay detecting human T-lymphotropic virus (HTLV) types I, II and divergent simian strains in the evaluation of individuals with indeterminate HTLV serology. J Med Virol 1997; 52:1-7.
35. Santos TJT, Costa CMC, Goubau P, Vandamme AM, Desmyter J, Van Dooren S
, et al.
Western blot seroindeterminate individuals for Human T-lymphotropic Virus 1/2 (HTLV-I/2) in Fortaleza (Brazil): a serological and molecular diagnostic and epidemiological approach. Braz J Infect Dis 2003;7:202-209.
36. Césaire R, Bera O, Maier H, Lezin A, Martial J, Ouka M,
et al
. Seroindeterminate patterns and seroconversions to human T-lymphotropic virus type I positivity in blood donors from Martinique, French West Indies. Transfusion 2002; 39:1145-1149.
37. Hjelle B, Mills R, Goldsmith C, Swenson S, Cyrus S. Primary isolation of human T-cell leukemia-lymphoma virus types I and II: use for confirming infection in seroindeterminate blood donors. J Clin Microbiol 1992; 30:2195-2199
)